Tech Days ’20 Virtual Program and Flyer available
The final program and flyer for the Tech Days ’20 Virtual are now available!
Read more: www.belnuc.be/tech-days-20-virtual
EANM ’20 Virtual for Technologists
This year, the EANM congress will once again provide a full program dedicated to technologists. The focus will be on topics that are important for current practice in the nuclear medicine field, a sector in which scientific and technological advancements have been great. A wide range of subjects will be covered during the Congress. These will include quality control and calibration of instrumentation for imaging and dosimetry, updates in pediatric and neuroendocrine tumor imaging and topics such as departmental organization and advanced competencies.
FANC/AFCN Patient Release Card
A FANC/AFCN technical decree published on August 3rd 2020 specifies the information that must appear on the discharge card given to a person who has been administered a radioactive product for radiotherapeutic purposes. You can download the FANC/AFCN templates in the “Library” on the BELNUC member section.
European Course on Lymphatic lmagings ln the Management of (Lymph-)Edemas And Benign Lymphatic Pathologies
To be held from the 23rd to the 28th of November 2020, this course offer training-teaching in the different imaging techniques of the lymphatic system (Lymphoscintigraphies, Nuclear Magnetic Resonance lymphangiographies, Lympho-Fluoroscopies and others) used in the management of (lymh)edemas (and other benign lymphatic pathologies), not only theoretical but also and above all practical (diagnoses integrated in the clinic and with well understood therapeutic purposes) with expert guidance, ultimately leading to the creation of a network (national and European) to exchange experience which also advances the body of knowledge of these lymphatic pathologies.
More information:
New ESMO guideline endorses PET/CT for bone imaging
A new European Society for Medical Oncology (ESMO) clinical practice guideline on Bone Health in Cancer has been published in Annals of Oncology, endorsing “FDG-PET-CT imaging as the most accurate way of assessing treatment response of hypermetabolic bone metastasis”.
EANM ’20 VIRTUAL dates announced
EANM’s virtual 2020 annual meeting will be held from October 22nd until October 30th.
EANM ’20 becomes VIRTUAL
EANM president prof. Wim Oyen announced today that even though technically allowed to run as a conference in Vienna, the difficult decision was taken that it is in the best interest of the entire Nuclear Medicine community to hold the EANM ’20 meeting virtual only. Further updates on https://eanm20.eanm.org.
EANM considers it “very likely that we can hold EANM’20 as an onsite congress”
In the first edition of its new weekly Wed@Noon newsletter, EANM announced that “the Austrian government has now approved up to 5,000 people attending events in closed spaces from September. Therefore, it is very likely that we can hold EANM’20 as an onsite congress. And you can rest assured that EANM will take all necessary measures to keep its participants safe and up-to-date.”
European Commission’s Joint Research Centre survey on radiopharmaceuticals for therapy
The European Commission’s Joint Research Centre, on request of the Council of the European Union, has launched a study and survey to increase the insight in the current and future use of radiopharmaceuticals for therapy in Europe: https://technopolisgroup.limequery.org/642128?lang=en.
ASCO 2020: 177Lu-PSMA more active than cabazitaxel in first analysis of randomized TheraP trial in mCRPC after docetaxel
Professor Michael Hofman presented the first results at the ASCO 2020 Virtual meeting from the randomized TheraP trial, comparing 177Lu-PSMA-617 with cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) after treatment with docetaxel. 177Lu-PSMA-617 was more effective than cabazitaxel, with fewer adverse events and PSA-PFS favoring 177Lu-PSMA-617.